Sales of Biogen’s BIIB key multiple sclerosis (“MS”) drugs like Tecfidera and Tysabri and spinal muscular atrophy (SMA) treatment, Spinraza, are being hurt due to competitive pressure, which is ...

Biogen has been involved in the MS therapies market for decades bringing its injectable Avonex (interferon-beta-1a) therapy to market for relapsing-remitting MS and active secondary progressive MS ...

Biogen also has a biosimilars segment producing generic drugs with a 4% YoY revenue growth of $202 million in 2024. Tecfidera and Vumerity are treatments for multiple sclerosis (MS). Its MS ...

Biogen Inc. has disclosed uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists with improved brain penetration reported to be useful for the treatment of multiple sclerosis.

With a market cap of $20.6 billion, Biogen specializes in treatments for conditions such as multiple sclerosis (MS), Alzheimer’s disease, spinal muscular atrophy, and other neurological disorders.

A cost-saving effort by NHS England to transition multiple sclerosis (MS) patients from Biogen Inc’s (NASDAQ:BIIB) Tysabri (natalizumab) to the biosimilar drug Tyruko has led to significant side ...

Biogen Inc. (NASDAQ:BIIB – Free Report ... and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.